Genpharmasec issued the notice for its 34th Annual General Meeting (AGM) to be held on September 29, 2026. The agenda includes the reappointment of Whole-time Director Sohan Chaturvedi and a special resolution to approve loans and guarantees up to ₹50 crore.

The Board of Directors approved the FY26 annual report in its meeting held on September 2, 2026. The company notified BSE Limited regarding the outcome of the meeting held at its registered office in Mumbai. The intimation was issued in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Outcomes

The Board of Directors considered and approved several critical governance tasks during the session:

• Fixed the date, time, and mode for the 34th Annual General Meeting (AGM)
• Approved the draft notice and calendar of events for the AGM
• Determined the cut-off date for voting rights entitlement
• Set commencement and closing dates for e-voting
• Approved the Directors Report for the year ended March 31, 2026
• Finalized the Annual Report for Financial Year 2025-26
• Closed the share transfer books and register of members
• Appointed a scrutinizer for e-voting at the 34th AGM
• Re-appointed Mr. Sohan Chaturvedi as Whole-time Director

AGM and Voting Details

The Board fixed Tuesday, September 29, 2026, at 11:00 am as the date for the 34th AGM to be conducted through Video Conferencing or Other Audio Visual Means. M/S Jaymin Modi & Co., Practicing Company Secretaries, was appointed as the scrutinizer for the e-voting process.

Management Changes

The Board approved the re-appointment of Mr. Sohan Chaturvedi (DIN: 09629728) as Whole-time Director for a term of three years effective April 26, 2027, subject to shareholder approval. Mr. Chaturvedi holds a Bachelor of Commerce and Master of Commerce from Agra University and has 17 years of experience in finance and accounting.

His proposed remuneration is up to ₹36 lakh per annum including perquisites, benefits, incentives, and other allowances. His last drawn remuneration was ₹19.71 lakh per annum. He currently serves as Whole-time Director & CFO.

Special Business

Shareholders will vote on a special resolution to approve providing loans, guarantees, or security under Section 185 of the Companies Act, 2013. The aggregate amount for these facilities to subsidiaries, associates, joint ventures, or group entities shall not exceed ₹50 crore.

The funds are intended for capital expenditure, working capital requirements, and purchase of fixed assets for principal business activities. The Board will determine the specific terms, interest rates, and conditions in the best interest of the company.

Rajesh Mirchumal Sadhwani, a promoter of Genpharmasec Ltd , acquired 65,00,000 equity shares through the open market on August 31 and September 1, 2026. The purchase increased his individual holding to 15.26% of the company’s total share capital.

The acquisition was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Sadhwani holds these shares alongside Sneha Sadhwani, who is designated as a Person Acting in Concert (PAC). Neither party reported any encumbrances, pledges, or liens on their holdings.

Shareholding Structure Changes

Before this transaction, Rajesh Mirchumal Sadhwani held 7,80,00,000 shares, representing 14.09% of the total voting capital. Sneha Sadhwani held 9,30,01,000 shares, accounting for 16.80%. Together, the promoter group controlled 30.88% of the company.

Following the open market purchases, Sadhwani’s stake rose to 8,45,00,000 shares. The combined holding of the promoter group increased to 17,75,01,000 shares, or 32.06% of the total diluted share capital. The company’s total equity share capital remains unchanged at ₹55,37,19,700, divided into 55,37,19,700 equity shares of Re. 1 each.

What the Numbers Show

The acquisition reflects a consolidation of control by the promoter group without altering the overall capital structure. With no convertible securities or warrants outstanding, the fully diluted voting capital matches the basic share capital. The absence of pledged shares indicates that the promoter group’s collateral position has not tightened during this period.